Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Portfolio Pulse from
Pacira BioSciences, which markets the non-opioid pain relief therapy EXPAREL, faces significant competitive threats from a newly approved generic version and a similar drug from Vertex. This has led to a dramatic decline in its share price from over $80 in mid-2022 to around $18.
November 25, 2024 | 6:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacira BioSciences' share price has significantly declined due to competitive threats to its main revenue-generating drug, EXPAREL, from a new generic and a similar drug by Vertex.
The approval of a generic version of EXPAREL and the impending approval of a similar drug by Vertex pose significant threats to Pacira's market share and revenue. This has led to a sharp decline in investor confidence, reflected in the substantial drop in share price.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100